Latest & greatest articles for Tongue Carcinoma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Tongue Carcinoma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Tongue Carcinoma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Tongue Carcinoma

1. Malignant Tumors of Tongue in Iranian Population Full Text available with Trip Pro

, the obtained statistics are highly reliable.During the years 2003 to 2008, a total number of 952 new cases of the tongue cancer were recorded in the CRC. Most cases are diagnosed in the sixth and seventh decades of life. 450 cases (47.2%) occurred in men and 489 cases (51.36%) in women. Four different types of malignant lesions (epithelial, salivary gland, hematopoietic and mesenchymal) were diagnosed. Epithelial tumors were the most prevalent malignancies (93%) of which squamous cell carcinoma (SCC) made (...) up 87.39% of all lesions. Salivary gland tumors had the second place with 3.15% of the total lesions.In Iranian population, squamous cell carcinoma is the most prevalent malignancy of tongue and it is notable that the ratio of female to male population was equal. These lesions were prevalent in the sixth and seventh decades of life. Thus screening examination of tongue by dentist especially in elderly patients is necessary for early detection of cancerous lesions.

2016 Iranian journal of cancer prevention

2. Squamous-Cell Carcinoma of the Tongue. Full Text available with Trip Pro

States N Engl J Med 0255562 0028-4793 AIM IM Aged Biopsy Carcinoma, Squamous Cell pathology Female Humans Tongue pathology Tongue Neoplasms pathology 2016 6 23 6 0 2016 6 23 6 0 2016 7 14 6 0 ppublish 27332922 10.1056/NEJMicm1513456 (...) Squamous-Cell Carcinoma of the Tongue. 27332922 2016 07 13 2016 06 23 1533-4406 374 25 2016 Jun 23 The New England journal of medicine N. Engl. J. Med. IMAGES IN CLINICAL MEDICINE. Squamous-Cell Carcinoma of the Tongue. e32 10.1056/NEJMicm1513456 Albuquerque Rui P P RP University of Birmingham, Birmingham, United Kingdom r.p.p.d.albuquerque@bham.ac.uk. Richards Andrea A University of Birmingham, Birmingham, United Kingdom r.p.p.d.albuquerque@bham.ac.uk. eng Case Reports Journal Article United

2016 NEJM

3. Early oral tongue cancer initially managed with surgery alone: Treatment of recurrence Full Text available with Trip Pro

Early oral tongue cancer initially managed with surgery alone: Treatment of recurrence To report T1-2N0 tongue cancer recurrences initially treated with surgery alone.Between 1990 and 2010, 27 patients at tertiary hospital referral center institution were treated with curative intent for locoregional recurrence after initial glossectomy with or without neck dissection for T1-2N0 tongue cancer. None had received adjuvant postoperative radiation as a component of the original treatment.Median (...) commonly treated with combined modality treatment (P = 0.005).Recurrence of early stage oral tongue cancer can be successfully salvaged in a majority of cases. Patients developing regional recurrence have significantly worse prognosis than those with local failures.

2016 World journal of otorhinolaryngology - head and neck surgery

4. Preliminary Results Suggest miR-139-5p Is a Viable Salivary Biomarker for Diagnosis of Tongue Squamous Cell Carcinoma (TSCC)

weeks after surgical removal of the tumor showed no statistically significant difference in miR-139-5p expression levels when compared to the control samples (p>0.05), and possessed sufficient power to distinguish from pre-operative TSCC saliva samples (AUC with 95% CI=0.713). Evidence Search ("saliva"[MeSH Terms] OR "saliva"[All Fields]) AND (("mouth neoplasms"[MeSH Terms] OR ("mouth"[All Fields] AND "neoplasms"[All Fields]) OR "mouth neoplasms"[All Fields] OR ("oral"[All Fields] AND "cancer"[All (...) other salivary biomarkers for early diagnosis of TSCC. Applicability Oral squamous cell carcinoma is a very common human malignancy with increasing prevalence. Despite numerous technological advances in the past 50 years, the 5-year survival rate for these patients has not changed. The study conducted by Duz et al. focused on tongue squamous cell carcinoma, which accounts for 41% of these carcinomas and is highly aggressive. Discovering a novel microRNA salivary biomarker could mean earlier

2016 UTHSCSA Dental School CAT Library

5. [High-dose rate brachytherapy in the treatment of mobile tongue cancer]

[High-dose rate brachytherapy in the treatment of mobile tongue cancer] Braquiterapia de alta tasa en el tratamiento de tumores de lengua móvil [High-dose rate brachytherapy in the treatment of mobile tongue cancer] Braquiterapia de alta tasa en el tratamiento de tumores de lengua móvil [High-dose rate brachytherapy in the treatment of mobile tongue cancer] Maceira-Rozas MC, Lema-Varela L. Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Maceira-Rozas MC, Lema-Varela L.. Braquiterapia de alta tasa en el tratamiento de tumores de lengua móvil. [High-dose rate brachytherapy in the treatment of mobile tongue cancer] Santiago de Compostela: Galician Agency for Health Technology Assessment (AVALIA-T). CT2014/04. 2014 Authors' objectives The main objective of this study was to assess the safety and effectiveness of HDRBT in the treatment

2014 Health Technology Assessment (HTA) Database.